Basel, Switzerland – Nov 2, 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today participation in four business conferences during the Month of November including company presentations at the LSX Inv€$tival Showcase in London, UK and the Piper Sandler Annual Healthcare Conference in New York, NY.

Bio Europe
Alentis will take part in the conference November 6–8, 2023 at the Messe München, Munich, Germany.

LSX Inv€$tival Showcase
Roberto Iacone, CEO of Alentis will give a company presentation at 13:00 GMT on Stage 3: Biotech Late Growth. The conference will be held at Old Billingsgate in London, UK on November 13, 2023.

Jefferies London Healthcare Conference
Alentis management will join the conference held on November 14-16, 2023 at the Waldorf Hilton in London, UK.

Piper Sandler Healthcare Conference
Roberto Iacone is scheduled to give a presentation on November 30, 2023 at 2:10 pm ET in the Staten Island Track, Kennedy 1, 4th Floor. Alentis management will attend the conference at the Lotte New York Palace in New York City on November 28 – December 2, 2023.

About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is the leading company pioneering a novel approach to modify and reverse the course of disease by targeting CLDN1, a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease.

Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit https://alentis.ch